Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of “Hold” by Brokerages

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have been assigned a consensus rating of “Hold” from the eight research firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, four have given a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $58.00.

Several research analysts have issued reports on STRO shares. Wall Street Zen cut shares of Sutro Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sutro Biopharma in a research note on Monday, December 1st. Wedbush reissued a “neutral” rating and set a $100.00 price objective (up from $20.00) on shares of Sutro Biopharma in a report on Tuesday, December 2nd. Finally, Wells Fargo & Company lowered their target price on Sutro Biopharma from $40.00 to $30.00 and set an “equal weight” rating for the company in a report on Tuesday, August 12th.

Sutro Biopharma Stock Down 7.7%

Shares of STRO opened at $8.66 on Monday. The business has a fifty day moving average of $9.26 and a 200 day moving average of $8.75. The company has a market cap of $73.70 million, a PE ratio of -0.33 and a beta of 1.62. Sutro Biopharma has a 52-week low of $5.23 and a 52-week high of $30.10.

Sutro Biopharma (NASDAQ:STRO) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.25). Sutro Biopharma had a negative return on equity of 852.70% and a negative net margin of 206.77%.The business had revenue of $9.69 million during the quarter, compared to analysts’ expectations of $10.14 million. As a group, research analysts anticipate that Sutro Biopharma will post -2.92 earnings per share for the current fiscal year.

Insider Activity

In other Sutro Biopharma news, Director Connie Matsui purchased 5,000 shares of the stock in a transaction on Wednesday, October 15th. The stock was acquired at an average price of $8.00 per share, with a total value of $40,000.00. Following the completion of the acquisition, the director owned 5,000 shares in the company, valued at $40,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders acquired 11,175 shares of company stock worth $89,598 over the last 90 days. Corporate insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Sutro Biopharma

A number of large investors have recently bought and sold shares of the company. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Sutro Biopharma in the second quarter worth $27,000. Savant Capital LLC purchased a new stake in Sutro Biopharma in the second quarter valued at $37,000. Bridgeway Capital Management LLC grew its position in Sutro Biopharma by 232.6% during the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after purchasing an additional 30,000 shares during the period. CWM LLC raised its stake in shares of Sutro Biopharma by 73.2% during the 2nd quarter. CWM LLC now owns 56,657 shares of the company’s stock valued at $40,000 after buying an additional 23,941 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its stake in shares of Sutro Biopharma by 174.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 60,617 shares of the company’s stock valued at $43,000 after buying an additional 38,561 shares during the last quarter. Hedge funds and other institutional investors own 96.99% of the company’s stock.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.